NASDAQ: ALMS · Life Sciences · 2 alerts · CIK 1847367
Share price
$5.14Close, Nov 16
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Alumis Inc. filings on SEC EDGAR ↗
Alumis Inc. reported total assets of $488.7 million as of September 30, 2026, supported by a significant increase in marketable securities following its IPO. The company is focused on the development of envudeucitinib (envu) for plaque psoriasis, with plans to submit a New Drug Application by the end of 2026.
Alumis Inc. reported third quarter 2026 financial results and confirmed it remains on track to submit a New Drug Application (NDA) for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 2026. The company ended the quarter with $344.4 million in cash and cash equivalents, which is expected to fund operations into 2027.
Term
Q3 2026
“Each additional readout from the ONWARD program has strengthened the consistent body of evidence supporting envudeucitinib’s highly competitive profile in moderate-to-severe plaque psoriasis. The new data presented in October showed early and durable improvement across scalp disease severity, itch resolution, and quality of life measures, building on a 54% PASI 100 response rate observed at 48 weeks of treatment. Our fourth-quarter 2026 NDA submission remains on track.”
Martin Babler, President and Chief Executive Officer of Alumis